<DOC>
	<DOCNO>NCT02118909</DOCNO>
	<brief_summary>This study design 2-part , open-label study assess effect pracinostat itraconazole ( part 1 ) pracinostat ciprofloxacin ( part 2 ) bioavailability pracinostat . Secondarily evaluate safety tolerability pracinostat administer itraconazole ciprofloxacin .</brief_summary>
	<brief_title>Evaluate Effects Itraconazole Ciprofloxacin Single-Dose PK Pracinostat Healthy Nonsmoking Subjects</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Healthy volunteer Continuous nonsmoker use nicotinecontaining product least 3 month prior first dose Body Mass Index ( BMI ) ≥ 18.5 ≤ 32.0 kg/m2 screening . Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign ECGs , deem PI . Female subject must nonchildbearing potential must undergo sterilization procedure least 6 month prior first dose postmenopausal amenorrhea least 1 year prior first dose follicle stimulate hormone ( FSH ) serum level consistent postmenopausal status . A non vasectomized , male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study medication . Understands study procedure inform consent form ( ICF ) , willing able comply protocol . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . History presence clinically significant medical psychiatric condition disease opinion PI . History illness , opinion PI , might confound result study pose additional risk subject participation study . History presence alcoholism drug abuse within past 2 year prior screen . History presence hypersensitivity idiosyncratic reaction study medication relate compound . History prolong QT syndrome require current medication may prolong QTc . History presence : myasthenia gravis ; convulsion . Female subject pregnant lactating . Positive urine cotinine , drug alcohol result screen checkin . Positive result screen HIV , HBsAg HCV . Seated blood pressure le 90/40 mgHg great 140/90 mmHg screening . Seated heart rate lower 40 bpm high 99 bpm screening . QTcF interval , &gt; 430 msec ( male ) &gt; 450 msec ( female ) deem clinical abnormal PI screen prior dose . Unable refrain anticipates use : Any drug , include prescription nonprescription medication , tobacco , antacid , herbal remedy , vitamin supplement begin approximately 14 day prior first dose study medication throughout study . Hormone replacement therapy allow postmenopausal female stable treatment least 1 month prior dose Day 1 Period 1 . Acetaminophen ( 2 g per 24 hour period ) may permit study . Any drug know significant inducer CYP enzyme , include St. John 's Wort , 28 day prior first dose study medication throughout study . Appropriate source consult PI designee confirm lack PK/pharmacodynamics interaction study medication . Have diet incompatible onstudy diet , opinion PI , within 28 day prior first dose study medication ( ) , throughout study . Hemoglobin , platelet count absolute neutrophil low limit normal screening . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) upper limit normal screening . Donation blood significant blood loss within 56 day prior first dose study medication . Participation another clinical trial within 28 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>